[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
June 14, 1999

Antidepressants and Smoking Cessation

Arch Intern Med. 1999;159(11):1254. doi:

In reply

We appreciate the letter by Gambassi and Bernabei regarding our recent trial on nortriptyline for smoking cessation. It is clear that there is a wide gap between our clinical understanding of antidepressants for smoking cessation and the basic science data on the mechanism of action, especially since most trials of the antidepressants for smoking cessation, including our own, excluded subjects with overt depression. We agree that more targeted drug therapy will be necessary to increase cessation rates. The rationale for testing serotonin reuptake inhibitors is interesting and led to a large trial using fluoxetine for smoking cessation that was completed a number of years ago. Portions of the data have been published1 and a full report is currently in preparation (Raymond Niaura, PhD, written communication, January 1999). Results of this study will be interesting and may clarify the role of these agents in smoking cessation.

First Page Preview View Large
First page PDF preview
First page PDF preview